Serum hepcidin levels are associated with obesity but not liver disease

Obesity

Volumn 22, Issue 3, 2014, Pages 836-841

  Vuppalanchi, Raj ^a   Troutt, Jason S ^b   Konrad, Robert J ^b   Ghabril, Marwan ^a   Saxena, Romil ^c   Bell, Lauren N ^a   Kowdley, Kris V ^d   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEPCIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER DISEASE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; BARIATRIC SURGERY; BODY MASS INDEX; COHORT STUDIES; FATTY LIVER; FEMALE; FERRITINS; HEPCIDINS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LINEAR MODELS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, MORBID;

EID: 84895785890     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20403     Document Type: Article

References (25)

1. Nemeth E,. Hepcidin biology and therapeutic applications. Expert Rev Hematol 2010; 3: 153-155.
2. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T,. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
3. Ganz T, Nemeth E,. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; Sep;1823(9): 1434-43.
4. Maliken BD, Nelson JE, Kowdley KV,. The hepcidin circuits act: balancing iron and inflammation. Hepatology 2011; 53: 1764-1766.
5. Ganz T, Nemeth E,. Iron sequestration and anemia of inflammation. Semin Hematol 2009; 46: 387-393.
6. Viatte L, Vaulont S,. Hepcidin, the iron watcher. Biochimie 2009; 91: 1223-1228.
7. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA,. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 1420-1429.
8. Zhang X, Rovin BH,. Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta 2010; 1800: 1262-1267.
9. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-796.
10. Senates E, Yilmaz Y, Colak Y, et al. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2011; 9: 287-290.
11. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR,. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011; 44: 1375-1379.
12. Zimmermann A, Zimmermann T, Schattenberg J, et al. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur J Intern Med 2011; 22: 305-310.
13. del Giudice EM, Santoro N, Amato A, et al. Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 2009; 94: 5102-5107.
14. Sanad M, Osman M, Gharib A,. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: a case control study. Ital J Pediatr 2011; 37: 34.
15. Nelson JE, Brunt EM, Kowdley KV,. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 2012; Nov;56(5): 1730-40.
16. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, Konrad RJ,. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 2010; 56: 1725-1732.
17. Troutt JS, Rudling M, Persson L, et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem 2012; 58: 1225-1232.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Organization WH,. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894 2000.
20. Aeberli I, Hurrell RF, Zimmermann MB,. Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children. Int J Obes (Lond) 2009; 33: 1111-1117.
21. Amato A, Santoro N, Calabro P, Grandone A, Swinkels DW, Perrone L, del Giudice EM,. Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int J Obes (Lond) 2010; 34: 1772-1774.
22. Tussing-Humphreys L, Frayn KN, Smith SR, et al. Subcutaneous adipose tissue from obese and lean adults does not release hepcidin in vivo. Sci World J 2011; 11: 2197-2206.
23. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Guzman G, Holterman AX, Braunschweig C,. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring) 2010; 18: 1449-1456.
24. Park KH, Sawada T, Kosuge T, Kita J, Shimoda M, Tomosugi N, Kubota K,. Surgical inflammation induces hepcidin production after abdominal surgery. World J Surg 2012; 36: 800-806.
25. Tan TC, Crawford DH, Franklin ME, et al. The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver Int 2012; 32: 1391-1399.